Tagged with GE

UK Ben Ellis, general manager at Lupin UK and Ireland, talks about the strategic challenges of transitioning from the sphere of generics to specialist pharma and how he hopes Lupin can change how it is perceived. Furthermore, he comments on the uncertainty Brexit brings to the industry and how healthcare should…

UK Sir John Chisholm, executive chair of Genomics England – a company set up and owned by the UK Department of Health to run the 100,000 Genomes Project, which aims to sequence 100,000 genomes from NHS patients with a rare disease and their families, and patients with cancer – discusses the…

Ecuador Pablo Ledesma del Pozo, managing director at PharmaBrand, discusses the company’s ambition to equal the business model of a multinational companies in the foreseeable future by commercializing their products as well as opening fully-integrated affiliates in neighboring countries, such as Chile, Peru, Bolivia and Central American countries. Pablo, you have…

Canada Heather Chalmers, vice president and general manager of GE Healthcare Canada, shares the company’s increasing focus on incorporating applied intelligence and digital analytics in its portfolio of innovative solutions, and how these can have significant effects on patient outcomes as well as the whole healthcare system. She further highlights the…

Ecuador Santiago Caviedes, Harvard graduate, founder and chief economist of Humboldt Management, a company awarded multiple times for the precision of its forecasts in Ecuador by international institutions, gives a detailed overview of the country’s current economic situation and positive outlook for the future. Mr. Caviedes describes the country as a…

UK Tim de Gavre, country head of Sandoz UK, discusses the role of biosimilars in driving innovation, the threats and opportunities of Brexit to the biosimilars industry, and how Sandoz partners with the NHS. In addition to your role at Sandoz, you are also one of the founding members of the…

Poland As east area director for the vast CEE market, Pawel Mazur explains how Accord Healthcare has gone from strength to strength in Poland, with the intention of becoming a top five generics company in the country by 2021. He also touches on the importance of a high-performing team, the exciting…

Estonia Riho Tapfer, director of the Association of Pharmaceutical Manufacturers of Estonia (APME), explains that a modern healthcare system and better medical care will require the widespread adoption of electronic health information which, in turn, allows for changes in important areas including prevention and more personalized care tailored specifically to a patient’s genetic…

Estonia Rauno Oja, managing director of AS EGeen, discusses the company’s geographical expansion during his tenure, turning to an international full-service CRO, EGeen’s commitment to high standards, and engagement with the community; carrying out communication activities on the ground in each country in which it operates. Rauno, you have worked for…

Baltics Roland Lepik, cluster head Baltics at Sandoz, discusses the company’s strategy that has allowed it to rank number one in the Estonian market along with the importance of ever-closer collaboration with key stakeholders to enhance the uptake of biosimilars. Roland, prior to joining Sandoz as Cluster Head Baltics you were…

India Murtaza Khorakiwala, managing director of Wockhardt, discusses the company’s vast international expertise in the manufacturing of pharmaceuticals and biopharmaceutical formulations in their 12 US FDA, UK MHRA and EMA compliant manufacturing facilities in India, as well as the out-licensing of its products into other regions to capture and penetrate new…

India As managing director of India’s fifth largest pharmaceutical company, Zydus Cadila’s Sharvil Patel shares his insights on his impressive internationalization strategy with a special focus on the US where Zydus recently received permission to conduct Phase II clinical studies of Lipaglyn, the first drug to treat patients with nonalcoholic steatohepatitis…